title: Botulinum toxin: A noninvasive option for the symptomatic treatment of salivary gland stenosis - a case report.
abstract: BACKGROUND
  A man diagnosed with Stensen's duct stenosis exhibited recurrent parotid swelling, invariably during meals. Previous parotid duct dilations and percutaneous radiotherapy were ineffective. Botulinum toxin (BTX) injections were injected into the affected gland to regulate salivary flow and reduce parotid swelling.
  
  
  METHODS
  BTX (22.5 units) was injected into the affected gland. A second treatment with 30 units BTX was carried out 7 weeks later. Two further injections followed after 4 months, respectively. The results were scored by the patient and evaluated in an examination.
  
  
  RESULTS
  The patient reported the disappearance of parotid swelling after 2 weeks of injections. This effect was maintained for 5 weeks after the first treatment and for 4 months after the following 2 treatments. There were no side effects.
  
  
  CONCLUSIONS
  Here we introduce BTX as a therapeutic option for the treatment of salivary duct stenosis when other therapies are ineffective and before opting for gland extirpation.
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Georg August University, Goettingen, Germany.
authors.forename: Jenny
authors.initials: J
authors.lastname: Kruegel
authors.forename: Jan
authors.initials: J
authors.lastname: Winterhoff
authors.forename: Sabrina
authors.initials: S
authors.lastname: Koehler
authors.forename: Philipp
authors.initials: P
authors.lastname: Matthes
authors.forename: Rainer
authors.initials: R
authors.lastname: Laskawi
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D003251:Constriction, Pathologic / Q000209:etiology / Q000473:pathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010309:Parotitis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D018987:Salivary Ducts
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A